Related Experiment Videos
[Evaluation of a latex agglutination assay method for the determination of plasmin/alpha 2 plasmin inhibitor complex]
F Murakami1, K Iijima, K Nakamura
1Department of Clinical Laboratory Medicine, Faculty of Medicine, Tottori University, Yonago.
Abstract:
We evaluated a latex agglutination assay method for concentration of plasmin/alpha 2 plasmin inhibitor complex (PPI) developed recently. The latex reagent consisted of two kinds of latex particles, one was coated with monoclonal antibody against plasmin (JIPPI-3) and another coated with monoclonal antibody against modified alpha 2 plasmin inhibitor (JIPPI-50). A correlation of concentrations of PPI between this method and ordinary EIA kit was very good (r = 0.969). Within-run precision of latex agglutination reagent also was good. The concentrations of PPI in plasmas of 40 in 43 normal subjects were 0-0.8 microgram/ml and others were 0.8-1.6 microgram/ml. Plasma levels of PPI were markedly elevated in patients with DIC. In addition, half of the patients with malignant tumors or liver diseases had increased levels of PPI. 16 of 32 cases with selected diseases (18 malignant tumors, 4 liver diseases, 2 infectious diseases, 2 cerebral contusions, 6 others) showed abnormal levels in PPI (> or = 0.8 microgram/ml) during several days preceding the elevation of FDP. It suggested that PPI could reflect fibrinolysis earlier than FDP. This latex agglutination assay is a simple and rapid method, and specific for the determination of PPI concentration as well as EIA method. We conclude that this assay method is very convenient for clinical use.
Insights
A new latex agglutination assay accurately measures plasmin/alpha 2 plasmin inhibitor complex (PPI). This method is simple, rapid, and detects elevated PPI levels earlier than FDP, aiding in early disease diagnosis.
Area of Science:
- Biochemistry
- Immunology
- Clinical Chemistry
Context:
- Plasmin/alpha 2 plasmin inhibitor complex (PPI) is a biomarker of fibrinolysis.
- Accurate quantification of PPI is crucial for diagnosing various diseases.
- Existing methods for PPI measurement can be complex or time-consuming.
Purpose:
- To evaluate a newly developed latex agglutination assay for PPI concentration.
- To assess the assay's accuracy, precision, and clinical utility compared to existing methods.
- To investigate the potential of PPI as an early indicator of fibrinolytic activity.
Summary:
- A latex agglutination assay using specific monoclonal antibodies demonstrated high correlation (r=0.969) with EIA for PPI quantification.
- The assay showed good within-run precision and established reference ranges for normal subjects.
- Elevated PPI levels were observed in patients with disseminated intravascular coagulation (DIC), malignant tumors, and liver diseases.
Impact:
- The assay identified elevated PPI levels in patients with malignant tumors and liver diseases.
- It suggested that PPI may indicate fibrinolytic changes earlier than Fibrin Degradation Products (FDP).
- This simple, rapid, and specific latex agglutination assay offers a convenient tool for clinical use.